FR2456522A1 - Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor - Google Patents

Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor

Info

Publication number
FR2456522A1
FR2456522A1 FR8010946A FR8010946A FR2456522A1 FR 2456522 A1 FR2456522 A1 FR 2456522A1 FR 8010946 A FR8010946 A FR 8010946A FR 8010946 A FR8010946 A FR 8010946A FR 2456522 A1 FR2456522 A1 FR 2456522A1
Authority
FR
France
Prior art keywords
acids
insulin
acid
pref
contg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR8010946A
Other languages
French (fr)
Inventor
Kenji Hara
Kyozaburo Tachibana
Seiji Naito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Kao Soap Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp, Kao Soap Co Ltd filed Critical Kao Corp
Publication of FR2456522A1 publication Critical patent/FR2456522A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Insulin prepns. comprise insulin, a carrier for absorption via mucous membranes, and 0.01-0.5 wt.% of >=1 selected from (a) 1-6C alkanoic acid, (b) lower hydroxy carboxylic acid, (c) inorganic acids selected from HCl, H3PO4, HN3, phosphotungstic acid and HClO4, (d) benzoic, phthalic and pyromellitic acids, (e) monochloro-, dichloro-, trichloro- and sulpho-acetic acids, (f) acrylic and maleic acids, and (g) pyruvic, furoic and picric acids. The carrier is pref. a suppository base. Pref. acids are 1-5C alkanoic acids (esp. acetic), tartaric acid, glycolic acid, HCl, HNO3 and monochloroacetic acid. The prepns. can also contain a surfactant and a protease inhibitor. They are pref. produced by dissolving insulin in an aq. soln. of the acid and incorporating the soln. into the carrier (esp. molten suppository base). The prepns. are esp. useful for rectal, intravaginal or sublingual admin. giving large reductions in blood sugar levels at low insulin concns.
FR8010946A 1979-05-18 1980-05-14 Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor Withdrawn FR2456522A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6129279A JPS55153712A (en) 1979-05-18 1979-05-18 Insulin pharmaceutical preparation and its production

Publications (1)

Publication Number Publication Date
FR2456522A1 true FR2456522A1 (en) 1980-12-12

Family

ID=13166964

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8010946A Withdrawn FR2456522A1 (en) 1979-05-18 1980-05-14 Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor

Country Status (3)

Country Link
JP (1) JPS55153712A (en)
DE (1) DE3018843A1 (en)
FR (1) FR2456522A1 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587621A1 (en) * 1985-09-09 1987-03-27 Berlin Chemie Veb PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL PREPARATIONS OF PEPTIDES HAVING INCREASED RESORPTION CAPACITY
EP0273202A2 (en) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
EP0302772A1 (en) * 1987-08-03 1989-02-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin composition for nasal administration
EP0332222A2 (en) * 1988-03-11 1989-09-13 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
WO2003105888A1 (en) 2002-06-18 2003-12-24 Aventis Pharma Deutschland Gmbh Acidic insulin preparations with improved stability
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US8013017B2 (en) 2001-05-31 2011-09-06 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56138110A (en) * 1980-03-28 1981-10-28 Teijin Ltd Suppository containing citric acid or salt thereof
JPS56138112A (en) * 1980-03-31 1981-10-28 Teijin Ltd Suppository containing ascorbic acid or sodium ascorbate
JPS56138115A (en) * 1980-03-31 1981-10-28 Teijin Ltd Suppository containing acidic amino acid or derivative thereof
JPS5780315A (en) * 1980-11-09 1982-05-19 Kyoto Yakuhin Kogyo Kk Absorption promotor for accelerating rectum absorption, base comprising it, and pharmaceutical preparation to be medicated to rectum
JPS6321704Y2 (en) * 1981-06-02 1988-06-15
SU1011126A1 (en) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Method of treating diabetes mellitus
JPS5838210A (en) * 1981-08-31 1983-03-05 Taiho Yakuhin Kogyo Kk Preparation for rectal administration
JPH0623092B2 (en) * 1984-03-19 1994-03-30 太陽化学株式会社 Suppository pharmaceutical composition
JPS61138863A (en) * 1984-12-11 1986-06-26 Honda Motor Co Ltd Engine body of internal-conbustion engine
JPH048302Y2 (en) * 1985-10-22 1992-03-03
JPS62158207A (en) * 1986-01-06 1987-07-14 Showa Yakuhin Kako Kk Composition for rectal administration
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
KR101152470B1 (en) 2003-08-13 2012-06-01 바이오콘 리미티드 - micro-particle fatty acid salt solid dosage formulations for therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL45481C (en) * 1900-01-01
JPS5315412A (en) * 1976-07-27 1978-02-13 Ono Pharmaceut Co Ltd Suppository for diabetics
FR2455897A1 (en) * 1979-05-10 1980-12-05 Kyoto Pharma Ind FATTY ACID ADJUVANT FOR PROMOTING THE ABSORPTION OF PHARMACOLOGICALLY ACTIVATED SUBSTANCES BY RECTUM, BASIC COMPOSITION FOR RECTAL ADMINISTRATION COMPRISING THIS ADJUVANT AND PHARMACEUTICAL COMPOSITION COMPRISING THIS ADJUVANT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL45481C (en) * 1900-01-01
JPS5315412A (en) * 1976-07-27 1978-02-13 Ono Pharmaceut Co Ltd Suppository for diabetics
FR2455897A1 (en) * 1979-05-10 1980-12-05 Kyoto Pharma Ind FATTY ACID ADJUVANT FOR PROMOTING THE ABSORPTION OF PHARMACOLOGICALLY ACTIVATED SUBSTANCES BY RECTUM, BASIC COMPOSITION FOR RECTAL ADMINISTRATION COMPRISING THIS ADJUVANT AND PHARMACEUTICAL COMPOSITION COMPRISING THIS ADJUVANT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1978 *

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587621A1 (en) * 1985-09-09 1987-03-27 Berlin Chemie Veb PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL PREPARATIONS OF PEPTIDES HAVING INCREASED RESORPTION CAPACITY
EP0273202A2 (en) * 1986-12-23 1988-07-06 Eugene J. Dr. Van Scott Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
EP0273202A3 (en) * 1986-12-23 1990-06-06 Eugene J. Dr. Van Scott Additives enhancing topical actions of therapeutic agents
EP0302772A1 (en) * 1987-08-03 1989-02-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin composition for nasal administration
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0332222A2 (en) * 1988-03-11 1989-09-13 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
EP0332222A3 (en) * 1988-03-11 1991-03-06 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
US5824646A (en) * 1988-03-11 1998-10-20 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US9456970B2 (en) 2001-05-31 2016-10-04 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US8013017B2 (en) 2001-05-31 2011-09-06 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
WO2003105888A1 (en) 2002-06-18 2003-12-24 Aventis Pharma Deutschland Gmbh Acidic insulin preparations with improved stability
US7476652B2 (en) 2002-06-18 2009-01-13 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
HRP20041200B1 (en) * 2002-06-18 2013-05-31 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations with improved stability
EP2305288A3 (en) * 2002-06-18 2013-12-11 Sanofi-Aventis Deutschland GmbH Acidic insulin preparations with improved stability
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
JPS55153712A (en) 1980-11-29
JPS5643443B2 (en) 1981-10-13
DE3018843A1 (en) 1980-11-20

Similar Documents

Publication Publication Date Title
FR2456522A1 (en) Insulin compsns. for admin via mucosa - contg. selected acids to increase absorption pref. also contg. a surfactant and a protease inhibitor
BR9200257A (en) PROCESS TO PRODUCE A TERPOLIMER, CLEANING COMPOSITION, AND COMPOSITION FOR WATER TREATMENT
JPS5257134A (en) Process for preparation of aromatic polycarboxylic acids
ATE41652T1 (en) PROCESS FOR THE MANUFACTURE OF AROMATIC DIOLS AND THEIR ESTER AND AETHER DERIVATIVES.
GB872355A (en) Improvements in or relating to the production of a tetrabasic acid and esters thereof
ZA843194B (en) Preparation of unsaturated acids and esters from saturated carboxylic acid derivatives,formaldehyde or its derivatives and oxygen
JPS5227715A (en) Process for preparation of gamma-halogeno-delta- unsaturated carboxylic acid ester and/or gamma-lactone derivatives
ES8306697A1 (en) Process for the production of methacrylic acid from isobutyraldehyde.
SU1145056A1 (en) Copper etching agent
WO1989002886A3 (en) 2-neopentylanthraquinone
NL7711922A (en) Oxidn. of mono:alkyl-benzene cpds. esp. toluene - with prod. subjected to esterification to facilitate recovery of benzyl alcohol etc.
NL7614457A (en) Oxidn. of mono:alkyl-benzene cpds. esp. toluene - with prod. subjected to esterification to facilitate recovery of benzyl alcohol etc.
FR2255298A1 (en) Oxidation of propylene with thallium salts - with reaction soln made basic before removal of propylene oxide to reduce acetone formn
GB573531A (en) Improvements in or relating to the reduction of the peracid content of oxidation reaction products
JPS53103444A (en) Alpha,alpha-di-substituted acetic acid esters and process for their preparation
JPS5589245A (en) 9,10-dihydroanthracene-2-alkanoic acid derivative
JPS5549336A (en) Preparation of 1, 2, 3, 4-butanetetracarboxylic acid
JPS53101388A (en) Novel cephalosporanic acid derivatives and process for their preparation
FR2035766A1 (en) Preparation of prenane derivs
JPS5227089A (en) Catalyst for production of carboxylic acid ester
ES8801178A3 (en) Carboxylic acid Ml-236b ester prepn.
JPS5356612A (en) Purification of maleic acid anhydride
GR3005588T3 (en)
JPS5441821A (en) 2-(3-alkylnitrosoureido)glucopyranoside derivative
JPS5217447A (en) Process for preparation of trans-4- aminomethylcyclohexane-carboxylic acid ester

Legal Events

Date Code Title Description
ST Notification of lapse